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Aims To determine 3-year event rates in outpatients with vascular disease enrolled in the REduction of Atherothrombosis
for Continued Health (REACH) Registry.
Methods
and results
REACH enrolled 67 888 outpatients with atherothrombosis [established coronary artery disease (CAD), cerebrovas-
cular disease, or peripheral arterial disease (PAD)], or with at least three atherothrombotic risk factors, from
44 countries. Among the 55 499 patients at baseline with symptomatic disease, 39 675 were eligible for 3-year
follow-up, and 32 247 had data available (81% retention rate). Among the symptomatic patients at 3 years, 92%
were taking an antithrombotic agent, 91% an antihypertensive, and 76% were on lipid-lowering therapy. For myocar-
dial infarction (MI)/stroke/vascular death, 1- and 3-year event rates for all patients were 4.2 and 11.0%, respectively.
Event rates (MI/stroke/vascular death) were signiﬁcantly higher for patients with symptomatic disease vs. those with
risk factors only at 1 year (4.7 vs. 2.3%, P , 0.001) and at 3 years (12.0 vs. 6.0%, P , 0.001). One and 3-year rates of
MI/stroke/vascular death/rehospitalization were 14.4 and 28.4%, respectively, for patients with symptomatic disease.
Rehospitalization for a vascular event other than MI/stroke/vascular death was common at 3 years (19.0% overall;
33.6% for PAD; 23.0% for CAD). For patients with symptomatic vascular disease in one vascular bed vs. multiple
vascular beds, 3-year event rates for MI/stroke/vascular death/rehospitalization were 25.5 vs. 40.5% (P , 0.001).
Conclusion Despite contemporary therapy, outpatients with symptomatic atherothrombotic vascular disease experience high
rates of recurrent vascular events and rehospitalizations.
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Vascular disease is a leading global cause of death and disability.
Coronary artery disease (CAD) and stroke are projected to be
the ﬁrst and second leading causes of death in the world,
1,2 and
most of these events occur in underdeveloped or developing
nations.
3,4 Steps to better treat vascular disease and prevent
these important events will have signiﬁcant public health impli-
cations as well as reduce the ﬁnancial impact for patients, health-
care systems, and governments.
Although lifestyle changes and targeted therapies reduce vascu-
lar disease and vascular events, such interventions are often either
underutilized or are not applied appropriately for some at-risk
populations.
5–7 A better understanding of how such therapies
are used and their impact on various populations could signiﬁcantly
inﬂuence medical practices, with the goal of preventing vascular
events.
The REduction of Atherothrombosis for Continued Health
(REACH) Registry is a contemporary international outpatient
study of patients either with vascular disease or at high risk for
developing vascular disease (Appendix).
8 Patients are treated
according to the best judgement and practices of their primary
care physicians and followed on a longitudinal outpatient basis.
No particular medications or interventions are tested as part of
the REACH Registry. The treatment setting is non-academic
outpatient physician practices. We used this unique registry to
determine the 3-year outcomes of a diverse international patient
population, with a focus on vascular events, risk factors, and
therapies. Our hypotheses were that despite widely available
therapies: (i) many patients receive suboptimal treatment and (ii)
this group of patients has a high rate of subsequent major vascular
events.
Methods
The design of the REACH Registry has been published previously.
9
Brieﬂy, REACH is an outpatient, non-specialist registry of patients
with either stable symptomatic vascular disease [CAD, stroke, transi-
ent ischaemic attack (TIA), peripheral artery disease (PAD)] or with
multiple risk factors for vascular disease (such as hypertension, dia-
betes mellitus, hyperlipidaemia, carotid stenosis, smoking, etc.).
Detailed data about medication use are recorded. The treatments
for each patient are determined by their medical practitioners, who
are typically their primary care physician. The REACH Registry primar-
ily enrolled patients who were not at a typical academic medical centre
or university hospital. Rather, the focus was on outpatients cared for
by non-specialists. Patients could not be enrolled in REACH if they
were participating in another clinical research study or if they were
currently hospitalized.
Patient enrolment began in December 2003 and ended in
December 2004. A total of 67 888 patients were enrolled from
5587 different physician practices in 44 countries. Each nation had
their own site-selection process designed to ensure diverse patient
selection in different settings (urban and rural) and to account for
the national patient and physician proﬁles and overall healthcare
environment. Local institutional review boards reviewed and approved
the protocol, and each enrolled patient was required to provide
informed consent.
Follow-up
Patients were followed annually (every 12+3 months) for key
outcome events and medication use in most countries, except in the
USA, where they were followed up every 6 months. Key outcome
events included myocardial infarction (MI), stroke, vascular death,
and rehospitalization for another vascular event or vascular procedure
[i.e. congestive heart failure, unstable angina, vascular surgery, percuta-
neous coronary intervention (PCI)]. Further details of how these
events were deﬁned have been published previously.
9 Patients were
not censored after they had an MI, stroke, or vascular death. Data
were also collected on serious bleeding events, which were deﬁned
as rehospitalization for bleeding and receipt of a blood transfusion,
or rehospitalization for any type of cerebral haemorrhage. Patients
were not censored if they had a serious bleeding event. Outcome
events were typically not adjudicated, although ischaemic stroke and
TIA had to be documented by a neurologist or recorded in hospital
records.
For this report, we focused mainly on follow-up events for
patients with symptomatic vascular disease at enrolment, since this
group makes up the majority of the REACH population, has much
higher event rates, and is often the target for most medical and
procedural interventions in routine clinical practice. This group of
patients is also the largest user of medical resources and healthcare
ﬁnances.
Central data collection was used with a standardized international
case report form. Demographic information, risk factors, medication
use, employment status, smoking, and weight were recorded at each
visit, along with key outcome events as noted earlier.
Statistical analysis
Continuous variables are expressed as mean+SD; categorical
variables are expressed as frequencies and percentages. Comparisons
of baseline characteristics and concomitant medications between the
numbers of symptomatic disease locations were made using x
2 tests.
When comparing event rates across different disease bed types,
patients were classiﬁed according to whether they had CAD, cerebro-
vascular disease (CVD), or PAD. Patients with polyvascular disease
could have been included in more than one category.
The study retention rate was calculated by comparing the number of
patients who completed the 3-year follow-up visit (or who died before
2-year follow-up) with the number of patients who were enrolled at
centres that agreed to participate in the 3-year follow-up phase of
the REACH Registry.
Cumulative event rates per 100 patient-years have been calculated
at 3 years for selected endpoints (vascular death, non-fatal MI, non-
fatal stroke, rehospitalization for another vascular event), according
to the number of symptomatic disease locations; the number of
events occurring within each period were added, divided by the
total duration of participation in the registry (measured in years) for
the patients, and multiplied by 100. All event rates were calculated
using the Cox proportional hazard model. Events rates are reported
as annualized rates, adjusted for age and sex. This adjustment was
accomplished through the corrected group prognosis method in the
Cox proportional hazards model previously described.
8 The difference
in hazard rates for selected endpoints according to the number of
symptomatic disease locations was tested using the Wald x
2 test
within the Cox proportional hazard model. All tests were two-sided
with a signiﬁcance threshold of P ¼ 0.05. Cumulative event curves
were constructed using the Kaplan–Meier approach. Statistical
analyses were performed using SAS v9.1 software (SAS Institute Inc.,
Cary, NC, USA).
Three-year follow-up and event rates 2319Results
At baseline, the REACH Registry enrolled 67 888 patients, of
which 55 499 had symptomatic disease, and 12 389 had asympto-
matic disease (Figure 1). At 3 years, 48 050 patients were eligible
for the 3-year follow-up analysis. Most of the attrition was
related to certain study sites choosing not to participate in
follow-up beyond 2 years, and 8712 patients did not attend the
3-year appointment (Figure 1). Of the 48 050 patients, 3-year
follow-up data were available for 36 608. Patients without com-
plete data at the 3-year follow-up included 8712 who did not
return for the 3-year appointment, 2301 who were deceased,
and 429 who withdrew consent. For this report, we focus mainly
on patients with symptomatic vascular disease (n ¼ 39 675),
since they have higher event rates and are most likely to beneﬁt
from secondary prevention strategies. Among the 39 675
symptomatic patients potentially available for 3-year follow-up,
data were available for 32 247, for an 81% retention rate.
Demographic data for symptomatic patients at baseline and
3 years are shown in Table 1. This population had high rates of
several vascular risk factors, particularly hypertension (80%)
and hypercholesterolaemia (70%). More than one in four
patients (26%) were obese, and a signiﬁcant minority (14%) of
them were current smokers. Thus a signiﬁcant portion of this
population had risk factors that were modiﬁable or treatable.
Medication use was relatively high, yet not universal (Table 2).
More than 90% of the symptomatic patients were taking an antihy-
pertensive agent at baseline and 91.1% at 3 years. The majority of
patients were also receiving some type of antithrombotic therapy
as well as a lipid-lowering drug. The use of ‘at least one antithrom-
botic’ remained consistent at 92.4% at baseline and 92.1% at year
3; the use of oral anticoagulation was also stable (12.9% at baseline
Figure 1 Patient ﬂow, drop-out, and follow-up over 3 years in the REACH Registry.
M.J. Alberts et al. 2320and 13.5% at 3 years); and the use of ‘at least one lipid-lowering
drug’ was fairly stable, at 72.9% for baseline and 75.9% at 3
years. Many patients were taking other cardiovascular agents as
well as antidiabetic medications. Although we do not have data
about adherence to speciﬁc medications, the overall rate of medi-
cation use appears to be quite high.
There were differences in medication use among symptomatic
patients based on gender, both at baseline and at 3 years. For
example, the use of any antiplatelet agent was higher in men vs.
women at baseline (93.5 vs. 90.1%, P , 0.0001) and at 3 years
(93.3 vs. 89.6%, P , 0.0001). This was not explained by higher
rates of anticoagulation use among women, since men had slightly
higher rates of oral anticoagulation use at baseline (13.3 vs. 12.2%,
P ¼ 0.0014) and at 3 years (13.8 vs. 12.8%, P ¼ 0.021). Similar
differences were seen for the use of any lipid-lowering drug
(73.6% in men vs. 71.4% in women at baseline, P , 0.0001; 76.9
vs. 73.8% at 3 years, P , 0.0001), and the use of any statin (69.2
vs. 66.4% at baseline, P , 0.0001; 73.0 vs. 69.5% at 3 years, P ,
0.0001).
The gender differences in the use of antithrombotics could not
be fully explained by differences in risk factors, since all of these
patients had symptomatic ischaemic vascular disease and likely qua-
liﬁed for some type of antithrombotic therapy based on existing
guidelines. For the use of lipid-lowering drugs, the percentage of
men and women with elevated total cholesterol at baseline was
similar (70.2% in men vs. 69.4% in women), indicating that other
factors may be affecting medication usage in men vs. women.
Among patients with symptomatic disease who were eligible for
3-year follow-up, 21 456 (54.1%) had only CAD, 8104 (20.4%) had
only CVD, and 2485 (6.3%) had only PAD at baseline. We also
found that 7630 had disease in more than one vascular bed,
which included 3997 with both CAD and CVD, 2271 with both
CAD and PAD, and 748 with the triad of CAD, CVD, and PAD
(Figure 2).
Event rates at 1 and 3 years
The rates of MI, stroke, vascular death, and rehospitalization for a
vascular event at 1 and 3 years for symptomatic patients are shown
in Table 3. For the composite endpoint of non-fatal MI, non-fatal
stroke, or vascular death (hence deﬁned as MI/stroke/vascular
death), the 1-year and 3-year event rates were 4.7 and 12.0%,
respectively (for patients enrolled with risk factors only, the
event rates for MI/stroke/vascular death were 2.3 and 6.0%, at 1
year and 3 years, respectively). When rehospitalization for a vascu-
lar event is added to the composite endpoint, more than one in
four patients at 3 years will experience one of these events. For
MI/stroke/vascular death/rehospitalization, the 1- and 3-year
event rates were 14.4 and 28.4%, respectively. Patients with PAD
had the highest 3-year event rate of MI/stroke/death/
Figure 2 Type and distribution of monovascular and polyvas-
cular disease at baseline in patients eligible for 3-year follow-up.
Data labels report the number of patients with each disease type.
................................................................................
Table 1 Baseline demographic and risk factor data for
REACH patients with symptomatic disease
Variable Symptomatic
patients in REACH
at baseline
Symptomatic
patients at 3-year
follow-up
n 55 499 39 675
Age, years
(mean+SD)
68.5+10.1 68.5+10.0
Men (%) 66.8 67.8
Hypertension (%) 80 79.3
Diabetes (%) 37.5 36.0
Elevated total
cholesterol (%)
70.2 68.7
Obesity  30
kg/m
2 (%)
27.4 25.9
Current smoker
(%)
14.4 14.3
Heart failure (%) 15.9 15.0
Atrial ﬁbrillation
(%)
11.7 11.4
................................................................................
Table 2 Medication use for symptomatic patients at
baseline and at 3-year follow-up
Medication
a (%) At
baseline
At 3
years
At least one antihypertensive drug 90.9 91.1
At least one antithrombotic drug 92.4 92.1
Aspirin alone 56.6 56.9
Aspirinþanother antiplatelet drug 14.5 12.8
Other antiplatelet drug alone 13.6 14.2
Oral anticoagulant drug 12.9 13.5
At least one lipid-lowering drug 72.9 75.9
Statin 68.3 71.9
Diabetic patients with at least one
antidiabetic drug
b
87.3 84.6
aDenominators may vary due to missing data.
bPercentage calculated from 14 282 diabetic patients at baseline and 10 628
diabetic patients at 3 years.
Three-year follow-up and event rates 2321rehospitalization, at 40.4%. These high rates are explained in part
by the fact that rehospitalization for a vascular event other than
MI/stroke/vascular death was a common occurrence at 3 years,
with rates of 21.3% for the entire symptomatic cohort, 33.6%
for patients with PAD, 23.0% for those with CAD, and 18.7%
for patients with CVD (Figure 3). In fact, rehospitalization for a vas-
cular event other than MI, stroke, or vascular death was more
common than the composite endpoint of MI, stroke, and vascular
death at both 1 and 3 years (Figure 3).
Analysis of event rates per 100 patient-years of follow-up
showed differences in subsequent events based on the vascular
bed initially involved (Figure 4). Patients with CVD were most
likely to have a subsequent stroke (2.8 events per 100 patient-
years), and those with PAD were most likely to have vascular
death (2.9 events per 100 patient-years). Non-fatal MI was
equally common among patients with either CAD or PAD (both
had rates of 1.2 events per 100 patient-years).
We found important gender differences in 3-year outcomes in
symptomatic patients. For the endpoint of MI/stroke/vascular
death, the 3-year event rate was 12.5% for men and 10.9% for
women (P ¼ 0.0007 when age adjusted). Much of this difference
was explained by the vascular death rate, which was 6.1% for
men and 4.6% for women (P , 0.0001). For the composite end-
point of MI/stroke/vascular death/rehospitalization, there was a
2% higher rate in men compared with women (29.1 vs. 27.0%,
P ¼ 0.0004) at 3 years.
Patients with polyvascular disease had the highest event rates at
1 and 3 years. For patients with symptomatic vascular disease in
one vascular bed compared with multiple vascular beds, the
3-year event rates for MI/stroke/vascular death/hospitalization
were 25.5 vs. 40.5% (P , 0.001). When patients with polyvascular
disease are compared with those with single-bed disease, the
3-year rates of vascular death are increased by 4%, the rate of
MI/stroke/vascular death increased by 7%, and the rate of MI/
stroke/vascular death/hospitalization increased by 15% (Figure 5).
............................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 3 Outcome events (age- and sex-adjusted) after 1 and 3 years of follow-up in REACH patients with symptomatic
disease
Outcome Total symptomatic population Subgroup
Any CAD Any CVD Any PAD
At 1 year n ¼ 53 211 n ¼ 38 602 n ¼ 18 013 n ¼ 7911
MI/stroke/vascular death 4.7 4.5 6.5 5.4
MI/stroke/vascular death/rehospitalization
a 14.4 15.2 14.5 21.1
Rehospitalization
a 11.4 12.4 10.1 19.2
At 3 years n ¼ 39 675 n ¼ 28 472 n ¼ 13 463 n ¼ 6118
MI/stroke/vascular death 12.0 11.6 15.4 14.8
MI/stroke/vascular death/rehospitalization
a 28.4 29.7 28.1 40.4
Rehospitalization
a 21.3 23.0 18.7 33.6
CAD, coronary artery disease; CVD, cerebrovascular disease; MI, myocardial infarction; PAD, peripheral arterial disease.
aRehospitalization for a vascular event other than MI, stroke, vascular death.
Figure 3 Rates of rehospitalization (excluding rehospitalization
for the primary endpoint of myocardial infarction/stroke/vascular
death) for symptomatic patients in REACH at 1- and 3-year
follow-up. Coronary artery disease, cerebrovascular disease,
and peripheral arterial disease groups include patients with
single bed as well as polyvascular disease.
Figure 4 Event rates per 100 patient-years at 3 years for
important vascular outcomes by the type of symptomatic
disease present at study entry. Coronary artery disease, cerebro-
vascular disease, and peripheral arterial disease groups include
patients with single bed as well as polyvascular disease.
M.J. Alberts et al. 2322Overthe3-yearcourseofREACH,patientswithPADonlyatbase-
linehadthehighestriskofprogressingtoinvolvementofothervascu-
lar beds, which mayexplain someofthe high event rates seenamong
this population. Almost 10% ofthe PADpatientsprogressed topoly-
vascular disease over 3 years, compared with 4% of patients with
either CAD or CVD at baseline. The most common progression
on a percentage basis was patients with PAD to develop CAD
(6.1%), followed by patients with PAD to develop CVD (3.8%), and
patients with CVD to develop CAD (3.7%). However, owing to the
greater number of patients with CAD at baseline, this group had
the largest number of patients who progressed to polyvascular
disease. For the CAD group, they next developed CVD in years 1,
3, and 2 (in decreasing order of occurrence).
Event rates varied by geographical region (Table 4). Eastern
Europe tended to have the highest overall event rates, whereas
Australia and Japan had the lowest. North America and Western
Europe also had above-average event rates despite the relatively
high use of medications and vascular procedures in these
regions. In general, the geographic differences in event rates
tended to mirror the prevalence of vascular risk factors and the
success in treating and controlling them.
Discussion
The data from this large, contemporary, international registry show
thatpatientswithsymptomaticvasculardiseasehavehighratesofsub-
sequentvasculareventsdespitethehighuseofvariousstandardmedi-
cationsandtreatments.Theseresultsraiseimportantquestionsabout
whether patients were actually treated according to guideline rec-
ommendations (as opposed to taking medications but not achieving
therapeuticgoals),about the needfor morewidespread use ofmedi-
cations, and the need for more potent and efﬁcacious medications.
8
This is particularly relevant for the REACH population, which had
high rates of several common vascular risk factors.
Besides using medications and other approaches (i.e. surgery
and endovascular procedures) for these patients, clearly more
Figure 5 Three-year rates of myocardial infarction/stroke/vas-
cular death, and myocardial infarction/stroke/vascular death/
rehospitalization for symptomatic patients with monovascular
or polyvascular disease.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
T
a
b
l
e
4
T
h
r
e
e
-
y
e
a
r
e
v
e
n
t
r
a
t
e
s
b
y
g
e
o
g
r
a
p
h
i
c
r
e
g
i
o
n
N
o
r
t
h
A
m
e
r
i
c
a
L
a
t
i
n
A
m
e
r
i
c
a
W
e
s
t
e
r
n
E
u
r
o
p
e
E
a
s
t
e
r
n
E
u
r
o
p
e
M
i
d
d
l
e
E
a
s
t
A
s
i
a
A
u
s
t
r
a
l
i
a
J
a
p
a
n
T
o
t
a
l
P
-
v
a
l
u
e
n
1
1
6
0
4
1
2
0
6
1
2
2
1
8
4
3
2
6
3
9
2
3
1
4
4
2
5
5
1
4
2
3
4
3
9
6
7
5
A
l
l
-
c
a
u
s
e
m
o
r
t
a
l
i
t
y
9
.
8
0
1
1
.
5
1
9
.
2
5
1
1
.
6
8
7
.
8
7
9
.
8
5
6
.
8
6
5
.
2
1
9
.
0
6
,
0
.
0
0
0
1
9
5
%
C
I
8
.
9
7
–
1
0
.
6
1
9
.
4
7
–
1
3
.
4
7
8
.
5
3
–
9
.
9
6
1
0
.
3
6
–
1
2
.
9
7
5
.
0
8
–
1
0
.
5
3
8
.
5
1
–
1
1
.
1
6
5
.
8
0
–
7
.
9
0
4
.
4
7
–
5
.
9
4
8
.
5
4
–
9
.
5
7
V
a
s
c
u
l
a
r
d
e
a
t
h
6
.
0
2
7
.
6
1
5
.
7
9
9
.
0
3
5
.
6
1
6
.
6
4
2
.
7
0
2
.
4
2
5
.
5
7
,
0
.
0
0
0
1
9
5
%
C
I
5
.
3
5
–
6
.
6
8
5
.
9
0
–
9
.
2
7
5
.
2
0
–
6
.
3
6
7
.
8
1
–
1
0
.
2
2
3
.
2
4
–
7
.
9
0
5
.
5
1
–
7
.
7
5
2
.
0
6
–
3
.
3
4
1
.
9
1
–
2
.
9
2
5
.
1
5
–
5
.
9
9
M
I
/
s
t
r
o
k
e
/
v
a
s
c
u
l
a
r
d
e
a
t
h
1
1
.
9
9
1
3
.
6
5
1
1
.
8
5
1
7
.
9
9
1
3
.
2
5
1
3
.
1
3
7
.
5
7
8
.
6
3
1
1
.
9
6
,
0
.
0
0
0
1
9
5
%
C
I
1
1
.
0
8
–
1
2
.
9
0
1
1
.
4
6
–
1
5
.
7
7
1
1
.
0
6
–
1
2
.
6
4
1
6
.
4
7
–
1
9
.
4
7
9
.
7
0
–
1
6
.
6
4
1
1
.
6
8
–
1
4
.
5
6
6
.
4
4
–
8
.
6
9
7
.
6
7
–
9
.
5
8
1
1
.
3
7
–
1
2
.
5
4
M
I
/
s
t
r
o
k
e
/
v
a
s
c
u
l
a
r
d
e
a
t
h
/
r
e
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
2
9
.
2
7
2
5
.
8
3
3
0
.
6
9
3
9
.
5
8
3
0
.
4
5
2
3
.
0
3
2
3
.
5
1
1
7
.
3
4
2
8
.
3
9
,
0
.
0
0
0
1
9
5
%
C
I
2
8
.
0
9
–
3
0
.
4
3
2
3
.
2
4
–
2
8
.
3
2
2
9
.
6
2
–
3
1
.
7
5
3
7
.
9
0
–
4
1
.
2
1
2
5
.
8
5
–
3
4
.
7
7
2
1
.
3
8
–
2
4
.
6
4
2
1
.
6
8
–
2
5
.
2
9
1
6
.
1
0
–
1
8
.
5
6
2
7
.
6
2
–
2
9
.
1
6
C
I
,
c
o
n
ﬁ
d
e
n
c
e
i
n
t
e
r
v
a
l
;
M
I
,
m
y
o
c
a
r
d
i
a
l
i
n
f
a
r
c
t
i
o
n
.
M
a
j
o
r
3
-
y
e
a
r
v
a
s
c
u
l
a
r
o
u
t
c
o
m
e
e
v
e
n
t
s
a
n
d
a
l
l
-
c
a
u
s
e
m
o
r
t
a
l
i
t
y
f
o
r
s
y
m
p
t
o
m
a
t
i
c
p
a
t
i
e
n
t
s
i
n
t
h
e
R
E
A
C
H
R
e
g
i
s
t
r
y
.
S
o
m
e
r
e
g
i
o
n
s
h
a
d
h
i
g
h
e
r
t
h
a
n
a
v
e
r
a
g
e
r
a
t
e
s
o
f
o
u
t
c
o
m
e
e
v
e
n
t
s
s
u
c
h
a
s
E
a
s
t
e
r
n
E
u
r
o
p
e
a
n
d
t
h
e
M
i
d
d
l
e
E
a
s
t
;
o
t
h
e
r
r
e
g
i
o
n
s
s
u
c
h
a
s
A
s
i
a
,
A
u
s
t
r
a
l
i
a
,
a
n
d
J
a
p
a
n
h
a
d
e
v
e
n
t
r
a
t
e
s
t
h
a
t
w
e
r
e
l
o
w
e
r
t
h
a
n
a
v
e
r
a
g
e
.
E
v
e
n
t
r
a
t
e
s
a
r
e
a
g
e
-
a
n
d
s
e
x
-
a
d
j
u
s
t
e
d
.
P
-
v
a
l
u
e
s
i
n
d
i
c
a
t
e
a
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
d
i
f
f
e
r
e
n
c
e
b
e
t
w
e
e
n
a
t
l
e
a
s
t
o
n
e
r
e
g
i
o
n
a
n
d
a
n
o
t
h
e
r
.
Three-year follow-up and event rates 2323attention should be paid to adopting and achieving healthier life-
styles. Improving diet, increasing exercise, and smoking cessation
are relatively easily available and inexpensive approaches to redu-
cing the occurrence of vascular events.
7,10 Nations and regions
that have improved their lifestyles have achieved lower rates of
coronary heart disease death and prevalence.
7,10–12
The use of various medications such as antithrombotics, antihy-
pertensives, and statins was fairly high in our study. We found small
but signiﬁcant differences in medication use by gender that were
not explained by differences in underlying risk factors. Although
the differences in the use of various medications by gender
varied by only a few percentage points, when extrapolated
across a global population affected by these treatable risk
factors, such differences could mean that millions of women may
not be receiving recommended therapies. Why women were
less likely to receive certain medications is unclear. Although it
could be argued that this did not translate into worse outcomes
for women (men had higher event rates at 3 years), it is certainly
possible that had the women been treated more aggressively, their
events rates might have been even lower. This is clearly an area
that requires further study using large international databases to
determine whether there is a gender bias in terms of medication
utilization. Prior studies have shown that women are less likely
to undergo cardiac catheterization and coronary artery bypass
surgery than men, further supporting gender bias in some care
settings.
13,14
We found high event rates at 3 years. More than one in four
patients with symptomatic vascular disease will have an MI,
stroke, vascular death, or be rehospitalized for another type of vas-
cular event at 3 years. These outcomes are even more pronounced
in those patients with PAD since 40% of these patients had a
serious vascular event at 3 years. Clearly improved emphasis on
the diagnosis and treatment of PAD is warranted.
On a global basis, these results represent tens of millions of vas-
cular events occurring each year. In addition to the medical and
personal impact of such events, the costs of recurrent events
and hospitalization or rehospitalization are enormous. The
annual cost of acute coronary syndromes in the USA is $150
billion, of which 60% is related to hospitalization.
15 The annual
cost for acute coronary syndromes is 3.3 billion E in Germany
and 3.1 billion E in Italy.
16 The cost for admission for stroke or
TIA ranges from 3500 to 5000 E annually in Germany.
17 Expenses
for PAD range from 1800 to 6200 E each year, of which 45% are
hospital related.
18 On the basis of these ﬁgures, even small
reductions in the number of these events could save national
health care systems billions of dollars and Euros each year.
Patients with polyvascular disease represent a particular chal-
lenge. These patients were at much higher risk of subsequent
events at both 1 year and 3 years. In addition, the progression
from monovascular to polyvascular disease, particularly for the
PAD group, was alarming, with almost 10% of patients showing
such progression over 3 years. Such trends will clearly place
additional healthcare burdens and costs on patients and healthcare
systems. These high-risk groups should be targeted for aggressive
identiﬁcation and treatment of all vascular risk factors.
19
There were signiﬁcant geographic differences in outcome
events. In general, Asian countries and Australia had lower event
rates, whereas Eastern Europe and the Middle East had higher
event rates. These differences were only partially explained by
increased prevalence of risk factors in those regions. For
example, at baseline, 85% of the symptomatic patients in Eastern
Europe had hypertension and 48% were overweight. Among symp-
tomatic patients from the Middle East, 81% had elevated choles-
terol and 49% had diabetes.
8 However, .97% of patients with
hypertension in Eastern Europe were receiving at least one antihy-
pertensive medication, and .85% of patients in the Middle East
were receiving at least one lipid-lowering agent.
8 This suggests
that the high event rates seen in some regions are not simply a
function of more risk factors or total lack of therapy. Baseline
data from the REACH Registry showed that many patients are
not treated to target goals for various risk factors such as hyper-
tension and hyperlipidaemia.
8 Questions about the effectiveness
of some therapies, adherence to medications, and the adoption
of healthier lifestyles should be addressed. Despite these issues,
the aggressive treatment of modiﬁable risk factors has the potential
to substantially reduce the risk of these vascular events.
20
Study limitations
Any registry with selection criteria has the potential to be affected
by ascertainment biases. We attempted to avoid such biases by
having broad inclusion criteria with an obvious focus on patients
with vascular disease and related risk factors. The diverse geo-
graphical distribution of enrolled patients and the wide variety of
physician practices would also tend to mitigate any large ascertain-
ment biases. Other limitations are that we could not document
adherence to taking prescribed medications or over-the-counter
medications, and most of the endpoints were not independently
adjudicated. However, participating physicians and study coordina-
tors were trained and instructed about measures to assess adher-
ence to medication regimens and how to deﬁne and diagnose
important endpoints.
To be enrolled in REACH, the participants had to be stable
outpatients. Targeting stable outpatients may have actually resulted
in an under-estimation of subsequent events, since it has been
well documented that the period immediately following an acute
coronary syndrome or ischaemic stroke is a time of high risk for
a subsequent vascular event.
21–23
Conclusions
The large multinational REACH Registry documented high rates of
recurrent vascular events at 3 years in patients with symptomatic
vascular disease. These events occurred in the setting of prevalent
risk factors but also high use of various medications. These results
point to the need for a multifaceted and aggressive approach to the
prevention and treatment of vascular risk factors and vascular
disease on a global basis. The high societal and medical costs of
these common diseases mandate a comprehensive programme
to reduce the occurrence of new and recurrent events.
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The pulmonary valve and the pulmonary artery
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A 65-year-old female was admitted to our hospital complaining of a progressive
dyspnoea.
On physical examination, there was a mild diastolic murmur over the pulmonary
area and the electrocardiogram was normal. Two-dimensional echocardiography
showed an aneurysmatic dilation of the pulmonary artery trunk (diameters of
59 mm   55 mm) and of its branches (35–38 mm each one), and a pulmonary
anomalous valve with a moderate incompetence. Cardiac magnetic resonance
conﬁrmed that the pulmonary valve had four cups of similar size (asterisk) with
a non-signiﬁcant pulmonary insufﬁciency, and a great aneurysm of the pulmonary
artery (arrow). Using a cardiac catheterism, a signiﬁcant pulmonary hypertension
was ruled out, and there was not a concomitant major pathology, therefore an
idiopathic origin of the aneurysm was considered.
The quadricuspid pulmonary valve is a rare congenital anomaly which is almost
always discovered at post-mortem studies (from 1 in 400 to 2000 autopsies).
Usually, it is an isolated anomaly, remains asymptomatic, and its echocardiography
diagnosisisverydifﬁcult;forthesereasons,itsdiagnosisisexceptionalinlivepeople.
On the other hand, the pulmonary artery aneurysm is also a rare anomaly of difﬁcult diagnosis because of its low prevalence (8 in
100 000 autopsies) and for being generally asymptomatic, but it can cause serious complications like sudden death.
To the best of our knowledge, the association of a quadricuspid pulmonary valve with an idiopathic pulmonary aneurysm in a live
patient has never been previously reported.
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